Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (2)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Kazakhstan (1)
Lithuania (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Russia (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Uzbekistan (1)
STADA is making strong progress on achieving sustainability targets
Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrat…
By launching the first medicine authorized in the EU for treating rare kidney disease
The European Commission (EC) has granted conditional marketing authorization for Kinpeygo®
Self-assessed burnout rates at all-time high; stress levels have increased;
more than one in three are struggling with sleep; appreciation f…
Many Parkinson’s patients across Europe are missing out on regular specialist advice on treating their condition, according to the findings …
Offers a comprehensive range of presentations to the EU adalimumab
biosimilars market
STADA has taken a significant step towards expanding its Specialty portfolio
Dr Christine Berndt joins STADA from June as Head of Global Development Specialties/Biosimilars
A citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie
Ignis and STADA’s Britannia sign exclusive licensing agreement to develop and commercialize subcutaneous apomorphine in mainland China, Hong…
STADA is preparing to meet demand for its expanding portfolio by investing almost EUR50 million in a supply-chain hub in Turda, Romania
Experienced expert Erin Federman will oversee commercialization of STADA’s biosimilars portfolio and pipeline